Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance

Si Han Wu, Jun Feng Bi, Timothy Cloughesy, Webster K. Cavenee, Paul S. Mischel

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses define the molecular architecture of GBM and highlight a central function for mechanistic target of rapamycin (mTOR) signaling. mTOR kinase exists in two multi- protein complexes, namely, mTORC1 and mTORC2. These complexes differ in terms of function, regulation and rapamycin sensitivity. mTORC1 is well established as a cancer drug target, whereas the functions of mTORC2 in cancer, including GBM, remains poorly understood. This study reviews the recent findings that demonstrate a central function of mTORC2 in regulating tumor growth, metabolic reprogramming, and targeted therapy resistance in GBM, which makes mTORC2 as a critical GBM drug target.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalCancer Biology and Medicine
Volume11
Issue number4
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance'. Together they form a unique fingerprint.

Cite this